Evaxion Biotech Files 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-02-25T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory-update

Related Tickers: EVAX

TL;DR

Evaxion Biotech (EVAX) filed a routine 6-K, confirming their foreign private issuer status and 20-F filings.

AI Summary

Evaxion Biotech A/S, a biotechnology company, filed a Form 6-K on February 25, 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Hoersholm, Denmark.

Why It Matters

This filing provides routine updates for investors and regulators regarding Evaxion Biotech's status as a foreign private issuer. It confirms their reporting structure and location.

Risk Assessment

Risk Level: low — This filing is a standard procedural report for a foreign private issuer and does not contain new financial or operational information that would typically increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What does it mean that Evaxion Biotech A/S is a 'foreign private issuer'?

A foreign private issuer is a foreign entity that is not a government, and its securities are not traded on a U.S. stock exchange, or it is a foreign issuer that has more than 50 percent of its outstanding voting securities held by U.S. residents.

What is Form 20-F?

Form 20-F is the annual report required to be filed by foreign private issuers with the SEC.

Where is Evaxion Biotech A/S's principal executive office located?

Evaxion Biotech A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does this filing indicate any new financial results or operational updates for Evaxion Biotech?

No, this Form 6-K filing primarily serves to report the company's status as a foreign private issuer and its filing requirements, rather than disclosing new financial or operational information.

From the Filing

0001171843-25-001051.txt : 20250225 0001171843-25-001051.hdr.sgml : 20250225 20250225081552 ACCESSION NUMBER: 0001171843-25-001051 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250225 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25659510 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_022525.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), and Form F-1 (File No. 333-283304), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On February 25, 2025, Evaxion Biotech A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits  Exhibit Number   Description       99.1   Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registra

View on Read The Filing